99 related articles for article (PubMed ID: 26318999)
1. Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng D; Andre P; Bateman TJ; Berger R; Chen YH; Desai K; Dewnani S; Ellsworth K; Feng D; Geissler WM; Guo L; Hruza A; Jian T; Li H; Metzger J; Parker DL; Reichert P; Sherer EC; Smith CJ; Sonatore LM; Tschirret-Guth R; Wu J; Xu J; Zhang T; Campeau LC; Orr R; Poirier M; McCabe-Dunn J; Araki K; Nishimura T; Sakurada I; Hirabayashi T; Wood HB
Bioorg Med Chem Lett; 2015 Nov; 25(22):5437-43. PubMed ID: 26318999
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel class of potent and selective FIXa inhibitors.
Zhang T; Andre P; Bateman TJ; Chen YH; Desai K; Ellsworth K; Geissler WM; Guo L; Hruza A; Jian T; Meng D; Parker DL; Qian X; Reichert P; Sherer EC; Shu M; Smith CJ; Sonatore LM; Tschirret-Guth R; Nolting AF; Orr R; Campeau LC; Araki K; Nishimura T; Sakurada I; Wood HB
Bioorg Med Chem Lett; 2015 Nov; 25(21):4945-4949. PubMed ID: 25978966
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.
Sakurada I; Endo T; Hikita K; Hirabayashi T; Hosaka Y; Kato Y; Maeda Y; Matsumoto S; Mizuno T; Nagasue H; Nishimura T; Shimada S; Shinozaki M; Taguchi K; Takeuchi K; Yokoyama T; Hruza A; Reichert P; Zhang T; Wood HB; Nakao K; Furusako S
Bioorg Med Chem Lett; 2017 Jun; 27(11):2622-2628. PubMed ID: 28408226
[TBL] [Abstract][Full Text] [Related]
4. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.
Kundu S; Wu S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804
[TBL] [Abstract][Full Text] [Related]
5. Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).
Watterson SH; Langevine CM; Van Kirk K; Kempson J; Guo J; Spergel SH; Das J; Moquin RV; Dyckman AJ; Nirschl D; Gregor K; Pattoli MA; Yang X; McIntyre KW; Yang G; Galella MA; Booth-Lute H; Chen L; Yang Z; Wang-Iverson D; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ
Bioorg Med Chem Lett; 2011 Dec; 21(23):7006-12. PubMed ID: 22018461
[TBL] [Abstract][Full Text] [Related]
6. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
Wang S; Beck R; Burd A; Blench T; Marlin F; Ayele T; Buxton S; Dagostin C; Malic M; Joshi R; Barry J; Sajad M; Cheung C; Shaikh S; Chahwala S; Chander C; Baumgartner C; Holthoff HP; Murray E; Blackney M; Giddings A
J Med Chem; 2010 Feb; 53(4):1473-82. PubMed ID: 20121197
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
[TBL] [Abstract][Full Text] [Related]
9. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.
Wang S; Beck R; Blench T; Burd A; Buxton S; Malic M; Ayele T; Shaikh S; Chahwala S; Chander C; Holland R; Merette S; Zhao L; Blackney M; Watts A
J Med Chem; 2010 Feb; 53(4):1465-72. PubMed ID: 20121198
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors.
Aubele DL; Truong AP; Dressen DB; Probst GD; Bowers S; Mattson MN; Semko CM; Sun M; Garofalo AW; Konradi AW; Sham HL; Zmolek W; Wong K; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Nguyen L; Bova MP; Hemphill SS; Basi G
Bioorg Med Chem Lett; 2011 Oct; 21(19):5791-4. PubMed ID: 21885276
[TBL] [Abstract][Full Text] [Related]
11. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa.
Neuenschwander PF
Biochemistry; 2004 Mar; 43(10):2978-86. PubMed ID: 15005634
[TBL] [Abstract][Full Text] [Related]
12. Tethering identifies fragment that yields potent inhibitors of human caspase-1.
Fahr BT; O'Brien T; Pham P; Waal ND; Baskaran S; Raimundo BC; Lam JW; Sopko MM; Purkey HE; Romanowski MJ
Bioorg Med Chem Lett; 2006 Feb; 16(3):559-62. PubMed ID: 16274992
[TBL] [Abstract][Full Text] [Related]
13. Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates.
Cui JJ; Araldi GL; Reiner JE; Reddy KM; Kemp SJ; Ho JZ; Siev DV; Mamedova L; Gibson TS; Gaudette JA; Minami NK; Anderson SM; Bradbury AE; Nolan TG; Semple JE
Bioorg Med Chem Lett; 2002 Oct; 12(20):2925-30. PubMed ID: 12270176
[TBL] [Abstract][Full Text] [Related]
14. Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program.
Zhang T; Liu Y; Yang X; Martin GE; Yao H; Shang J; Bugianesi RM; Ellsworth KP; Sonatore LM; Nizner P; Sherer EC; Hill SE; Knemeyer IW; Geissler WM; Dandliker PJ; Helmy R; Wood HB
J Med Chem; 2016 Mar; 59(5):1818-29. PubMed ID: 26871940
[TBL] [Abstract][Full Text] [Related]
15. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
16. Tricyclic indole and dihydroindole derivatives as new inhibitors of soluble guanylate cyclase.
Spyridonidou K; Fousteris M; Antonia M; Chatzianastasiou A; Papapetropoulos A; Nikolaropoulos S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4810-3. PubMed ID: 19560917
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors.
Hird AW; Aquila BM; Block MH; Hennessy EJ; Kamhi VM; Omer CA; Laing NM; Saeh JC; Sha L; Yang B
Bioorg Med Chem Lett; 2014 Apr; 24(7):1820-4. PubMed ID: 24631189
[TBL] [Abstract][Full Text] [Related]
18. The structure of synthetic oligosaccharides in relation to factor IXa inhibition.
Hérault JP; Gaich C; Bono F; Driguez PA; Duchaussoy P; Petitou M; Herbert JM
Thromb Haemost; 2002 Sep; 88(3):432-5. PubMed ID: 12353072
[TBL] [Abstract][Full Text] [Related]
19. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
